Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin

Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C

(2013) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

(2013) Edward J. Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2

(2012) Yasunori Yamaguchi et al.   HEPATOLOGY RESEARCH

Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection

(2012) Monika Rau et al.   JOURNAL OF HEPATOLOGY

An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin

(2012) Eiichi Ogawa et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment

(2012) Antonio DʼAvolio et al.   THERAPEUTIC DRUG MONITORING

Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis

(2011) Masayuki Kurosaki et al.   ANTIVIRAL THERAPY

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin

(2011) Masayuki Kurosaki et al.   ANTIVIRAL THERAPY

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future

(2011) Vincent Di Martino et al.   HEPATOLOGY

Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring

(2011) Alessandra Mangia et al.   HEPATOLOGY

Ribavirin concentration in the later stages of 48 week pegylated interferon- 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response

(2011) N. Furusyo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan

(2011) Tsugiko Oze et al.   JOURNAL OF GASTROENTEROLOGY

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy

(2011) Takahiro Azakami et al.   JOURNAL OF MEDICAL VIROLOGY

Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C)

(2011) A. Birerdinc et al.   JOURNAL OF VIRAL HEPATITIS

The Effect ofITPAPolymorphisms on the Enzyme Kinetic Properties of Human Erythrocyte Inosine Triphosphatase Toward its Substrates ITP and 6-Thio-ITP

(2011) Jaap A. Bakker et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

ITPA Polymorphism Affects Ribavirin-Induced Anemia and Outcomes of Therapy—A Genome-Wide Study of Japanese HCV Virus Patients

(2010) Hidenori Ochi et al.   GASTROENTEROLOGY

Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction

(2010) Alexander J. Thompson et al.   GASTROENTEROLOGY

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

(2010) Maria Buti et al.   HEPATOLOGY

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

(2010) Jacques Fellay et al.   NATURE

Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response

(2009) Peter Ferenci et al.   GASTROENTEROLOGY

Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin

(2009) T. Oze et al.   JOURNAL OF VIRAL HEPATITIS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C

(2008) J. Morello et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY